Avastin

Roche condemns 'act of counterfeiting' as authorities in Pakistan crack down on unapproved Avastin use
Roche condemns 'act of counterfeiting' as authorities in Pakistan crack down on unapproved Avastin use
Fierce Pharma
Roche
Avastin
Pakistan
drug counterfeiting
Flag link:
Genentech reveals positive results from cancer combo therapy trial
Genentech reveals positive results from cancer combo therapy trial
Clinical Trials Arena
Genentech
Tecentriq
Avastin
liver cancer
hepatocellular carcinoma
Flag link:
FDA rejects Biocon and Viatris' Avastin biosimilar after inspection question marks
FDA rejects Biocon and Viatris' Avastin biosimilar after inspection question marks
Endpoints
FDA
Biocon
Viatris
Avastin
biosimilars
drug manufacturing
Flag link:
Roche’s Tecentriq to be filed for early-stage liver cancer
Roche’s Tecentriq to be filed for early-stage liver cancer
Pharmaphorum
Roche
Tecentriq
Avastin
clinical trials
liver cancer
Flag link:
FDA Approves Avastin Biosimilar for Six Types of Cancer
FDA Approves Avastin Biosimilar for Six Types of Cancer
Pharmacy Times
FDA
biosimilars
Vegzelma
Avastin
non-small cell lung cancer
glioblastoma
metastatic colorectal cancer
cervical caner
metastatic renal cell carcinoma
Flag link:
Microcap's effort to take on Eylea with Avastin biosimilar faces significant FDA roadblock
Microcap's effort to take on Eylea with Avastin biosimilar faces significant FDA roadblock
Endpoints
Outlook Therapeutics
Avastin
biosimilars
wet age-related macular degeneration
Roche
bevacizumab
Flag link:
Roche Wakes Up to New Competition as FDA Approves Amneal’s Avastin Biosimilar
Roche Wakes Up to New Competition as FDA Approves Amneal’s Avastin Biosimilar
BioSpace
Amneal
FDA
bevacizumab-maly
Genentech
Roche
Avastin
biosimilars
Flag link:
Merck fleshes out Keytruda win in first-line cervical cancer, adding more firepower to its early cancer push
Merck fleshes out Keytruda win in first-line cervical cancer, adding more firepower to its early cancer push
Endpoints
ESMO
Merck
Keytruda
Roche
Avastin
cervical cancer
Flag link:
Outlook heads to regulators with eye-friendly Avastin
Outlook heads to regulators with eye-friendly Avastin
EP Vantage
Outlook Therapeutics
Avastin
age-related macular degeneration
FDA
Lucentis
Flag link:
Roche nabs frontline OK for Avastin/Tecentriq in common liver cancer, besting an old Bayer drug
Roche nabs frontline OK for Avastin/Tecentriq in common liver cancer, besting an old Bayer drug
Endpoints
Roche
Avastin
Tecentriq
metastatic hepatocellular carcinoma
liver cancer
FDA
Flag link:
Bio-Thera Solutions announces positive top-line results for BAT1706, a proposed biosimilar to Avastin
Bio-Thera Solutions announces positive top-line results for BAT1706, a proposed biosimilar to Avastin
Pharmaceutical Business Review
BAT1706
Bio-Thera Solutions
Avastin
Roche
non-squamous non-small cell lung cancer
biosimilars
Flag link:
Pfizer launches biosimilars to Roche’s ‘big three’ cancer drugs in US
Pfizer launches biosimilars to Roche’s ‘big three’ cancer drugs in US
Pharmaforum
Pfizer
Roche
biosimilars
Avastin
Zirabev
Herceptin
Trazimera
Rituxan
Ruxience
Flag link:
Innovent and Coherus Strike Licensing Agreement for Avastin Biosimilar
Innovent and Coherus Strike Licensing Agreement for Avastin Biosimilar
BioSpace
China
Innovent Biologics
Coherus Biosciences
biosimilars
Avastin
Flag link:
Roche shows Tecentriq/Avastin combo helps liver cancer patients live longer
Roche shows Tecentriq/Avastin combo helps liver cancer patients live longer
Endpoints
Roche
Tecentriq
Avastin
liver cancer
China
Bayer
Nexavar
clinical trials
Flag link:
Roche's Tecentriq scores a first-in-class double win in new liver cancer patients
Roche's Tecentriq scores a first-in-class double win in new liver cancer patients
Fierce Pharma
Roche
liver cancer
Tecentriq
immuno-oncology
Avastin
Nexavar
Flag link:
ESMO: AZ, Merck's Lynparza chases Avastin combo nod with big ovarian cancer win
ESMO: AZ, Merck's Lynparza chases Avastin combo nod with big ovarian cancer win
Fierce Pharma
Roche
Avastin
ovarian cancer
AstraZeneca
Merck
Lynparza
ESMO
Flag link:
Amgen biosimilar debut boosted by UnitedHealthcare coverage switch
Amgen biosimilar debut boosted by UnitedHealthcare coverage switch
Biopharma Dive
insurers
Amgen
biosimilars
Avastin
Herceptin
Roche
UnitedHealthcare
Flag link:
Roche doomsday is here: Long-feared Herceptin, Avastin biosims bust into U.S. market
Roche doomsday is here: Long-feared Herceptin, Avastin biosims bust into U.S. market
Fierce Pharma
Herceptin
Avastin
Roche
biosimilars
Allergan
Amgen
Flag link:
Another Biosimilar Approval From FDA, Another Unknown Launch Date
Another Biosimilar Approval From FDA, Another Unknown Launch Date
RAPS.org
Pfizer
Zirabev
biosimilars
FDA
Roche
cancer
Avastin
Flag link:
New insight into a struggling AstraZeneca anti-VEGF drug could expand its use in cancer
New insight into a struggling AstraZeneca anti-VEGF drug could expand its use in cancer
Fierce Biotech
AstraZeneca
Avastin
anti-VEGF
cediranib
Flag link:

Pages